Literature DB >> 8069533

Lymphocyte activation-31P magnetic resonance studies of energy metabolism and phospholipid pathways.

O Kaplan1, J S Cohen.   

Abstract

31P NMR spectra of perfused lymphocytes embedded in alginate capsules and activated by interleukin-2 (IL-2) are remarkably different from those of control lymphocytes. The main differences are the appearance and gradual increase of phosphodiester signals, glycerophosphocholine and glycerophosphoethanolamine. These metabolic changes also occur following perfusion with phorbol ester and after incubation with phytohemagglutinin (PHA) and are not dependent on a special growth medium. Nifedipine, a calcium channel blocking drug, inhibits the effects of PHA, but not of IL-2. There are no NMR spectral differences between peripheral lymphocytes, stimulated for 3 weeks, and tumor-infiltrating lymphocytes. Thus, sustained accelerated turnover of phosphatidylcholine (PC) and phosphatidylethanolamine is an inherent feature of the activation process. 31P NMR spectra of lymphocytes are characterized by a low phosphocholine signal. Perfusion studies with high concentrations of choline and the use of dapsone, an inhibitor of phosphocholine cytidyltransferase, indicate that choline kinase plays a key role in regulating PC synthesis in human lymphocytes.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8069533     DOI: 10.1006/immu.1994.1015

Source DB:  PubMed          Journal:  Immunomethods        ISSN: 1058-6687


  2 in total

1.  Quantitation of glycerophosphorylcholine by flow injection analysis using immobilized enzymes.

Authors:  A Mancini; F Del Rosso; R Roberti; P Caligiana; A Vecchini; L Binaglia
Journal:  Mol Cell Biochem       Date:  1996-09-20       Impact factor: 3.396

Review 2.  MRI and MRS of intact perfused cancer cell metabolism, invasion, and stromal cell interactions.

Authors:  Marie-France Penet; Tariq Shah; Flonne Wildes; Balaji Krishnamachary; Santosh K Bharti; Jesus Pacheco-Torres; Dmitri Artemov; Zaver M Bhujwalla
Journal:  NMR Biomed       Date:  2019-01-28       Impact factor: 4.044

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.